One investigates the effects of anti-IL-33 monoclonal antibody compared with placebo, on the annualized rate of moderate-to-severe acute exacerbations of COPD over up to 52 weeks of treatment (ClinicalTrials.gov: NCT03546907). This evidence concerns the gene IL33 and chronic obstructive pulmonary disease.